Literature DB >> 8136263

Interleukin-4 inhibits apoptotic cell death and loss of the bcl-2 protein in B-chronic lymphocytic leukaemia cells in vitro.

P Panayiotidis1, K Ganeshaguru, S A Jabbar, A V Hoffbrand.   

Abstract

When monoclonal B cells from B-chronic lymphocytic leukaemia (B-CLL) patients are cultured in vitro, they die by apoptosis. Apoptotic cell death occurred in the B cells from 20/24 B-CLL patients after 26-30 h in in vitro culture, with 14.3-59.0% (mean 33.6%) of their DNA being fragmented in approximately 180 base pair multimers. After 8-10 d culture, 90-100% of the B-CLL cells were dead. Cell death and DNA fragmentation were inhibited in the presence of 0.5-5 ng/ml human recombinant interleukin-4 (IL-4) and viable monoclonal B cells could be maintained in culture up to 3 weeks. At 5 ng/ml, IL-4 reduced DNA fragmentation after a 26-30 h culture to 2.2-33.3% (mean 14.9%). IL-4 inhibited apoptosis without stimulating cell proliferation. In four patients the cells were resistant to apoptosis in vitro and they could be maintained for up to 4 weeks in culture medium alone. DNA fragmentation in all patients was increased in the presence of the RNA synthesis inhibitor actinomycin-D. Western blot analysis of cell lysates showed expression of the bcl-2 protein in all 11 B-CLL patients studied. However, during culture, bcl-2 protein levels were preserved only in patients resistant to apoptosis and were reduced in those susceptible to apoptosis. Reduction of bcl-2 protein levels was inhibited in cells cultured in the presence of IL-4. These data offer an explanation for the difference between the long life in vivo and rapid death in vitro of B-CLL cells and indicate that IL-4 may participate in the extended survival of these non-dividing cells in vivo.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8136263     DOI: 10.1111/j.1365-2141.1993.tb03330.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  19 in total

1.  Protection of porcine endothelial cells against apoptosis with interleukin-4.

Authors:  Sylvester M Black; Barbara A Benson; Damé Idossa; Gregory M Vercellotti; Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2011 Nov-Dec       Impact factor: 3.907

Review 2.  Cancer-stromal interactions: role in cell survival, metabolism and drug sensitivity.

Authors:  Wan Zhang; Peng Huang
Journal:  Cancer Biol Ther       Date:  2011-01-15       Impact factor: 4.742

3.  Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease.

Authors:  Shahryar Kiaii; Aniruddha Choudhury; Fariba Mozaffari; Eva Kimby; Anders Osterborg; Håkan Mellstedt
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

4.  Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765.

Authors:  Sarah E M Herman; Amber L Gordon; Erin Hertlein; Asha Ramanunni; Xiaoli Zhang; Samantha Jaglowski; Joseph Flynn; Jeffrey Jones; Kristie A Blum; Joseph J Buggy; Ahmed Hamdy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2011-03-21       Impact factor: 22.113

Review 5.  Probing lymphocyte biology by genomic-scale gene expression analysis.

Authors:  A Alizadeh; M Eisen; D Botstein; P O Brown; L M Staudt
Journal:  J Clin Immunol       Date:  1998-11       Impact factor: 8.317

Review 6.  Aberrant responses of human lymphocytic neoplasms to cytokine regulation.

Authors:  P C Nowell; J S Moore
Journal:  Immunol Res       Date:  1998       Impact factor: 2.829

Review 7.  Immune reconstitution in chronic lymphocytic leukemia.

Authors:  John C Riches; Alan G Ramsay; John G Gribben
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

8.  The activity of atorvastatin and rosiglitazone on CD38, ZAP70 and apoptosis in lymphocytes of B-cell chronic lymphocytic leukemia in vitro.

Authors:  Irfan Yavasoglu; Gokhan Sargin; Gurhan Kadikoylu; Aslihan Karul; Zahit Bolaman
Journal:  Med Oncol       Date:  2013-05-19       Impact factor: 3.064

9.  PKC-β as a therapeutic target in CLL: PKC inhibitor AEB071 demonstrates preclinical activity in CLL.

Authors:  Dalia El-Gamal; Katie Williams; Taylor D LaFollette; Matthew Cannon; James S Blachly; Yiming Zhong; Jennifer A Woyach; Erich Williams; Farrukh T Awan; Jeffrey Jones; Leslie Andritsos; Kami Maddocks; Chia-Hsien Wu; Ching-Shih Chen; Amy Lehman; Xiaoli Zhang; Rosa Lapalombella; John C Byrd
Journal:  Blood       Date:  2014-07-07       Impact factor: 22.113

10.  High-content screening identifies kinase inhibitors that overcome venetoclax resistance in activated CLL cells.

Authors:  Sina Oppermann; Jarkko Ylanko; Yonghong Shi; Santosh Hariharan; Christopher C Oakes; Patrick M Brauer; Juan C Zúñiga-Pflücker; Brian Leber; David E Spaner; David W Andrews
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.